While we share your commitment to addressing the high cost of prescription drugs, we strongly oppose A8136, legislation that would explicitly authorize the use of copay maximizer programs in New York’s health insurance market.
Questions for FTC/DOJ listening sessions on lowering Americans’ drug prices through competition
Copay accumulator and maximizer programs block manufacturer copay assistance from counting toward a patient’s deductible or out-of-pocket maximum. As a result, patients face sudden and unaffordable cost spikes mid-year, while PBMs, insurers, and often third-party vendors retain the financial value of the assistance. These programs are commonly deployed by vertically integrated entities, raising concerns that internal financial incentives are being prioritized over patient affordability and therapeutic continuity.
Testimony in support of South Carolina H3934 to ban copay accumulators
By passing H 3934, South Carolina will join 24 other states, the District of Columbia, and Puerto Rico in protecting consumers purchasing insurance on the private market. This legislation ensures that copay assistance counts toward cost-sharing obligations, preventing patients from facing insurmountable financial barriers to their medications. For people with HIV, hepatitis, and other chronic conditions, reliable access to medication is critical. Individuals with HIV and hepatitis B require lifelong drug regimens, while those with hepatitis C can be cured in as little as 8 to 12 weeks. Yet high deductibles and cost-sharing requirements often make these treatments unaffordable, even for insured patients. Copay assistance is a lifeline, particularly in today’s challenging economic climate, where inflation and rising costs are straining household budgets.
Support for Rhode Island bill banning copay accumlators
When patients are forced to forego their medications due to high costs, the consequences are severe—not just for individual health outcomes, but also for public health and healthcare system costs. Policies that limit access to copay assistance exacerbate these challenges, disproportionately affecting those who are already vulnerable. House Bill 6209 represents an essential safeguard against harmful insurer practices, ensuring equitable access to life-saving treatments for Rhode Island residents.
Testimony in support of New Jersey A5217 to ban copay accumulators
The HIV+Hepatitis Policy Institute, a leading organization advocating for equitable and affordable healthcare for individuals living with or at risk of HIV, hepatitis, and other chronic health conditions, strongly supports Assembly Bill 5217. This vital legislation ensures that health insurers accept and count payments made on behalf of patients toward their deductibles and out-of-pocket maximums.